$ZYME $MRK Zymeworks entered a new collab granting Merck the right to develop multispecific antibody therapeutic candidates using Zymeworks’ Azymetric and EFECT platforms.

Merck to pay undisclosed upfront + up to $891M in milestones &amp; exercise fees.

PR: https://t.co/to1v2kAY8Y https://t.co/on4eIQol9l